# A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

> **NCT04208061** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran Etexilate
- **DRUG:** DRV/COBI
- **DRUG:** Ritonavir
- **DRUG:** Darunavir

## Key facts

- **NCT ID:** NCT04208061
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-18
- **Primary completion:** 2021-03-25
- **Final completion:** 2021-04-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04208061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04208061, "A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT04208061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*